La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
West Pharmaceutical Services Salute del bilancio
Salute finanziaria criteri di controllo 6/6
West Pharmaceutical Services ha un patrimonio netto totale di $2.6B e un debito totale di $205.8M, che porta il suo rapporto debito/patrimonio netto a 8%. Le sue attività totali e le sue passività totali sono rispettivamente $3.5B e $912.6M. L'EBIT di West Pharmaceutical Services è $610.7M rendendo il suo rapporto di copertura degli interessi -28.8. Ha liquidità e investimenti a breve termine pari a $446.2M.
Informazioni chiave
8.0%
Rapporto debito/patrimonio netto
US$205.80m
Debito
| Indice di copertura degli interessi | -28.8x |
| Contanti | US$446.20m |
| Patrimonio netto | US$2.58b |
| Totale passività | US$912.60m |
| Totale attività | US$3.49b |
Aggiornamenti recenti sulla salute finanziaria
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31Recent updates
West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Is West Pharmaceutical Services, Inc. (NYSE:WST) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 14Is There Now An Opportunity In West Pharmaceutical Services, Inc. (NYSE:WST)?
Aug 31Do West Pharmaceutical Services' (NYSE:WST) Earnings Warrant Your Attention?
Aug 18Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $1.5B ) di WST superano le sue passività a breve termine ( $633.7M ).
Passività a lungo termine: Le attività a breve termine di WST ( $1.5B ) superano le sue passività a lungo termine ( $278.9M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: WST ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di WST si è ridotto da 13.6% a 8% negli ultimi 5 anni.
Copertura del debito: Il debito di WST è ben coperto dal flusso di cassa operativo ( 365.6% ).
Copertura degli interessi: WST matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.